Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Deep brain stimulation (DBS), a proven treatment for movement disorders, also holds promise for the treatment of psychiatric and cognitive conditions. However, for DBS to be clinically effective, it may require DBS technology that can alter or trigger stimulation in response to changes in biomarkers sensed from the patient's brain. A growing body of evidence suggests that such adaptive DBS is feasible, it might achieve clinical effects that are not possible with standard continuous DBS and that some of the best biomarkers are signals from the cerebral cortex. Yet capturing those markers requires the placement of cortex-optimized electrodes in addition to standard electrodes for DBS. In this Perspective we argue that the need for cortical biomarkers in adaptive DBS and the unfortunate convergence of regulatory and financial factors underpinning the unavailability of cortical electrodes for chronic uses threatens to slow down or stall research on adaptive DBS and propose public-private partnerships as a potential solution to such a critical technological gap.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413772 | PMC |
| http://dx.doi.org/10.1038/s41551-024-01314-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Self-phosphorylating DNAzyme DK1 enables programmable multi-analyte readout via PfAgo.
Biosens Bioelectron
September 2025
Department of Biological Sciences, Faculty of Science, National University of Singapore, 117543, Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, 117597, Singapore; Precision Medicine Translational Research Programme (TRP), Yong Loo Lin School
DNAzymes possessing kinase-like activities have long held theoretical promise, yet their practical implementation has remained significantly limited. Notably, DNAzyme kinase 1 (DK1), discovered over two decades ago, exhibits a unique self-phosphorylation capability upon encountering specific substrates like ATP, but its broad-based and programmable applications have not yet been fully realized. In this study, we innovatively couple DK1's autophosphorylation mechanism with the PfAgo to establish a novel programmable cascade sensing platform named RASTEN (Robust pfAgo-based Strategy for POC Testing Non-nucleic Acid and Nucleic Acid).
View Article and Find Full Text PDFFrom adaptive deep brain stimulation to adaptive circuit targeting.
Nat Rev Neurol
September 2025
Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Deep brain stimulation (DBS) substantially improves motor symptoms and quality of life in people with movement disorders such as Parkinson disease and dystonia, and it is also being explored as a treatment option for other brain disorders, including treatment-resistant obsessive-compulsive disorder, Alzheimer disease and depression. Two major developments are currently driving progress in DBS research: first, the framework of adaptive DBS, which senses brain activity to infer the momentary state of the symptoms of a patient and reacts by adapting stimulation settings, and second, the concept of connectomic DBS, which identifies brain circuits that should optimally be stimulated to reduce specific symptoms. In this Perspective, we propose a unified framework that combines these two concepts.
View Article and Find Full Text PDFIndividualizing Programming of Responsive Neurostimulation and Deep Brain Stimulation Therapies in Epilepsy.
J Clin Neurophysiol
July 2025
Department of Neurology, Duke University, Durham, North Carolina, U.S.A.
Responsive neurostimulation and deep brain stimulation have emerged as effective intracranial neuromodulation therapies for drug-resistant epilepsy when surgical resection is not an option. However, programming these devices presents unique challenges in epilepsy. Without immediate feedback and a vast programming space, clinicians are often tasked with fine-tuning device settings without clear, mechanistic guidance and limited clinical time.
View Article and Find Full Text PDFTowards individualized deep brain stimulation: A stereoencephalography-based workflow for unbiased neurostimulation target identification.
bioRxiv
August 2025
UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Objectives: Deep brain stimulation (DBS) is increasingly being used to treat a variety of neuropsychiatric conditions, many of which exhibit idiosyncratic symptom presentations and neural correlates across individuals. Thus, we have utilized inpatient stereoelectroencephalography (sEEG) to identify personalized therapeutic stimulation sites for chronic implantation of DBS. Informed by our experience, we have developed a statistics-driven framework for unbiased stimulation testing to identify therapeutic targets.
View Article and Find Full Text PDFAdaptive deep brain stimulation timed to gait phase improves walking in Parkinson's disease.
medRxiv
August 2025
Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
Gait dysfunction in Parkinson's disease (PD) is a major source of disability and is often resistant to traditional deep brain stimulation (DBS). Here, we report a novel neuromodulation paradigm, gait-phase-synchronized adaptive DBS (aDBS), that dynamically modulates stimulation amplitude during contralateral leg swing. In five individuals with PD, we identified personalized neural biomarkers of gait phase from cortical and pallidal field potentials and embedded them into a chronically implanted bidirectional neurostimulator.
View Article and Find Full Text PDF